Physician profile
Ryan P Basham
NPI 1083876098
$2,917.52
in general payments reported to CMS, 2019-2025
24 companies · $883 in 2025
The $883 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $187 · 2021: $114 · 2022: $171 · 2023: $611 · 2024: $630 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $642.86 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Alcon Vision LLC | $351.07 | 2019-2025 | Tryptyr, Eysuvis, Rocklatan |
| Abbvie INC. | $348.03 | 2023-2025 | Durysta, Lumigan, Alphagan P |
| Biotissue Holdings INC. | $312.88 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $174.65 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Aerie Pharmaceuticals, INC. | $168.79 | 2019-2021 | |
| Glaukos Corporation | $117.57 | 2022-2025 | Idosetr |
| Sun Pharmaceutical Industries INC. | $98.33 | 2019-2025 | Xelpros, Cequa |
| Oyster Point Pharma, INC. | $81.56 | 2023-2025 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $79.90 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $78.37 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $71.94 | 2019-2023 | |
| Thea Pharma INC. | $53.93 | 2024-2025 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $46.14 | 2019-2022 | |
| Sight Sciences, INC. | $43.66 | 2024 | Omni Surgical System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Shire North American Group INC | $37.09 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35.89 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $35.02 | 2023 | Tecnis Iol, Veritas Vision System |
| Ivantis, INC | $25.35 | 2020 | |
| Akorn, INC. | $23.96 | 2019 | |
| Kala Pharmaceuticals, INC. | $17.46 | 2021 | |
| Horizon Therapeutics Plc | $17.31 | 2023 | Tepezza |
| Amgen INC. | $16.96 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Basham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.